Belgian atopic dermatitis guidelines

Acta Clin Belg. 2024 Feb;79(1):62-74. doi: 10.1080/17843286.2023.2285576. Epub 2024 Jan 2.

Abstract

Atopic dermatitis (AD) is one of the most common, bothersome and difficult to treat skin disorders. Recent introduction of new systemic treatments has revolutionized the management of AD. The goal of this guideline is to provide evidence-based recommendations for the management of patients suffering from atopic dermatitis that easily can be implemented in clinical practice. These recommendations were developed by 11 Belgian AD experts. Comments of all experts on the proposed statements were gathered, followed by an online voting session. The most relevant strategies for the management and treatment of AD in the context of the Belgian health care landscape are discussed. General measures, patient education and adequate topical treatment remain the cornerstones of AD management. For moderate to severe AD, the introduction of biologics and JAK inhibitors show unprecedented efficacy, although currently access is limited to a subgroup of patients meeting the reimbursement criteria.

Keywords: Atopic dermatitis; diagnosis; eczema; guideline; therapy.

Publication types

  • Review

MeSH terms

  • Administration, Cutaneous
  • Belgium
  • Dermatitis, Atopic* / drug therapy
  • Humans